Bristol Myers Squibb

News

BMS gets FDA OK for first LAG-3 checkpoint inhibitor

Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co.

News

Sour taste for Nektar as bempegaldesleukin flunks ph3 test

Four years ago, Bristol-Myers Squibb paid $1.85 billion upfront to claim rights to Nektar's bem

News

BMS' cash cow Revlimid faces first generic rivals in US

Bristol-Myers Squibb's blood cancer blockbuster Revlimid is finally facing generic competition in the US, which will eat into revenues from a drug that made a massive $12.8 billion in sales

News

BMS carves out a neoadjuvant niche for Opdivo in NSCLC

Bristol-Myers Squibb's Opdivo has been playing second fiddle to Merck & Co's Keytruda in the non-small cell lung cancer (NSCLC) market for years, but now it has a chance to take the lim

News

BMS builds case for mavacamten label ahead of FDA decision

Bristol-Myers Squibb has new data backing up the value of mavacamten for obstructive hypertrophic cardiomyopathy (HCM), as it waits for a delayed verdict on its marketing application for th

News

FDA fast tracks Bayer's oral anticoagulant asundexian

The FDA has granted fast-track status to Bayer's oral Factor Xia inhibitor asundexian, which is in phase 2 testing as an anticoagulant that could offer safety advantages over current drugs.

BMS gets FDA OK for first LAG-3 checkpoint inhibitor

Sour taste for Nektar as bempegaldesleukin flunks ph3 test

BMS' cash cow Revlimid faces first generic rivals in US

BMS carves out a neoadjuvant niche for Opdivo in NSCLC

BMS builds case for mavacamten label ahead of FDA decision

FDA fast tracks Bayer's oral anticoagulant asundexian

AZ claims another win for Imfinzi in frontline liver cancer

Using AI-driven synthetic personas to take your insights fur...

Bristol Myers Squibb

Editor's Picks